109
Participants
Start Date
October 31, 2009
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
BIM 23A760
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
UZ Leuven, Leuven
National Medical University n.a. M.I.Pirogov, Vinnitsa
Academy of Medical Science of Ukraine, Department of Clinical Endocrinology, Kharkiv
Pituitary Center, Los Angeles
Oregon University, Dept. of Endocrinology and Neurosurgery, Portland
Massachusetts General Hospital / Neuroendocrine Unit, Boston
Centre Hospitalier Universitaire de Liège, Liège
Hospital Universitário Clementino Fraga Filho, Rio de Janeiro
Hospital das Clínicas de São Paulo, São Paulo
University Hospital Olomouc, Clinic of Internal Medicine, Olomouc
General University Hospital, Clinic of Internal Medicine,, Prague
Hôpital Bicêtre, Le Kremlin-Bicêtre
Hôpital de la Timone, Marseille
P. Stradins Clinical University Hospital, Riga
Kaunas Medical University Hospital, Kaunas
"Vilnius University Hospital Santariskiu Klinikos", Vilnius
UIM Endocrinología Experimental, Hospital de Especialidades, Mexico City
Insituto Nacional de Neurologia y Neurocirugia, México
Department of Endocrinology, Erasmus MC, Rotterdam
Voivodeship Specialistic Hospital No 3, Rybnik
"C.I. Parhon National Institute of Endocrinology", Bucharest
Karolinska University Hospital, Stockholm
"Administration of Medical Services and Rehabilitation of ARTEM", Kyiv
Lead Sponsor
Ipsen
INDUSTRY